Abstract
During 1/1/-3/31/2022, SARS-CoV-2 Omicron BA.1 (CoVID-19 OBA.1) was pandemic in USA. Two study objectives are to determine if CoVID-19 OBA.1 was associated with a change in: (1) adherence to oral tetrabenazine analogue (TBZa) used to treat Huntington's Disease with chorea (HDc) or Tardive Dyskinesia (TDD) patients serviced by specialty pharmacy's medication therapy management program (SPMTM) and (2) patient-reported quality of life (QOL). A retrospective, observational, pre-/post-design study of HDc,TDD patient adherence to oral TBZa and associated QoL was conducted at beginning of and during CoVID-19 OBA.1 pandemic. Patient assessments (PA) occurred at start of care (SOC) and follow-up (F-U) 7 days before dispenses. PA included EQ-5D-5L QoL metrics. Descriptive statics used to calculate QoL dimensional means before and after starting TDZa and then on F-U SPMTM. Differences in means represented patient perceived changes in QoL. The medication possession ratio (MPR) was calculated using the F-U from both the Pre- and During-CoVID-19 OBA.1. MPR = 0.96 prior to index time and was 0.93 During-CoVID-19 OBA.1 (3.1%). 238 PA were done During-CoVID-19 OBA.1 (280 HDc,TDD patients, 22 SOC, 250 F-U). Differences in QoL means Pre- vs During-CoVID-19 OBA.1 were: Mobility +0.0081 (0.81%), Self-Care +0.002 (0.2%), Usual Activities -0.0022 (0.22%), Pain/Discomfort -0.0103 (1.03%), Anxiety/Depression -0.0089 (0.89%), Overall Health State -0.07 (0.09%). Note: “-” = improvement; ”+”=worsened in Dimensions 1-5; “+” = improvement and ”-“ = worsened in Overall Health state. Percentages = absolute values. MPR decreased by 3.1% compared to Pre-CoVID-19 OBA.1. Pre- and During-CoVID-19 OBA.1 MPR were higher than the industry standard of >0.9.5 On average, patients reported Mobility and Self-Care worsened but improved on Usual Activities, Pain/Discomfort and Anxiety/Depression dimensions of EQ-5D-5L. Over-all Health rating improved slightly by 0.09%. Explanations for worsened QoL metrics are discussed.7 Additional studies are suggested.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
